DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies

Dow Jones

06/30

DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies.

The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years.

During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter.

The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 29, 2026 16:25 ET (20:25 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2647630288"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2647630288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2647630288?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647630288","market":"hk","top_or_hot":-1,"title":"DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DBVT\">DBV Technologies</a> is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n</p>\n<p>\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n</p>\n<p>\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n</p>\n<p>\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies to Incorporate FDA Feedback on Patch for Treat Peanut Allergies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 04:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DBVT\">DBV Technologies</a> is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n</p>\n<p>\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n</p>\n<p>\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n</p>\n<p>\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 29, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647630288","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647630288","pubTimestamp":1782764700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies.The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years.During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter.The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies.Write to Kelly Cloonan at kelly.cloonan@wsj.com Dow Jones NewswiresJune 29, 2026 16:25 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","DBV":"Invesco DB G10 Currency Harvest Fund","DBVT":"DBV Technologies S.A."},"translate_title":"DBV Technologies将纳入FDA对治疗花生过敏贴剂的反馈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBVT":0.9,"LABU":1.5,"DBV":1.5},"content_text":"DBV Technologies is working to incorporate feedback from the Food and Drug Administration before seeking marketing approval for a patch to treat peanut allergies. \n\n\n  The biopharmaceutical company said Monday it has had continuing discussions with the FDA in recent weeks to prepare to submit a Biologics License Application for its Viaskin Peanut Patch for children ages four through seven years. \n\n\n  During their collaboration, the FDA provided valuable input and has not requested additional information, DBV said. The company now expects to file its application for the treatment in the third quarter. \n\n\n  The patch is designed to introduce microgram amounts of a biologically active compound to the immune system through the skin to address peanut allergies. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 29, 2026 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}